Uncategorised - European Medical Journal

Continue
1st October 2013

Pharmacological Treatment of Idiopathic Pulmonary Fibrosis - An Update

Idiopathic pulmonary fibrosis (IPF) is the most common and most lethal fibrosing interstitial pneumonia, with a mortality rate that exceeds that of many…
1st October 2013

Novel Treatment Options for Autoimmune Pulmonary Alveolar Proteinosis

Pulmonary alveolar proteinosis (PAP) is a diffuse pulmonary disease, characterised by the accumulation of lipoproteinaceous material in the distal air…
1st October 2013

Advances in the Diagnosis of Tuberculosis and Drug Resistance

Countries in which tuberculosis (TB) is common are countries with lower economical conditions and less laboratory opportunities, so diagnostic tests for…
1st October 2013

Airway Clearance in the Intensive Care Unit

Mechanically-ventilated patients in the intensive care unit (ICU) may suffer from retained secretions from several causes. Airway clearance techniques…
1st August 2013

Delayed Erythroid and Platelet Response to Eculizumab in Paroxysmal Nocturnal Haemoglobinuria - A Case Report and Literature Review

Paroxysmal nocturnal haemoglobinuria (PNH) is an acquired clonal disorder of haemopoiesis characterised by haemolytic anaemia, thrombophilia and variable…
1st August 2013

The Chemokine CCL17/TARC as a Biomarker in Hodgkin Lymphoma

Classical Hodgkin lymphoma (cHL) is a lymphoproliferative disorder hallmarked by a distinctive type of neoplastic cells, the Hodgkin and Reed/Sternberg…
1st August 2013

Pain Management in Patients with Sickle Cell Disease - A Review

Pain is defined, by the International Association for the Study of Pain (IASP), as an ‘unpleasant sensitive and emotional experience, associated with or…
1st August 2013

Treatment of HIV-Associated Burkitt Lymphoma

Burkitt lymphoma (BL) is a highly aggressive B-cell malignancy, occurring with increased frequency among patients infected with HIV. For several years…
1st August 2013

RNA Interference (RNAi): An Effective Way to Develop Rational Combination Therapies with Hypomethylating Agents in Acute Leukaemias and Myelodysplastic Syndrome

Therapeutic progress in aggressive myeloid malignancies such as acute myeloid leukaemia (AML), myelodysplastic syndrome (MDS) and advanced…
1st August 2013

Preventing Infections in Higher-Risk Myelodysplastic Syndrome Patients Treated with Hypomethylation Agents

Hypomethylation agents became the standard of care for patients with high-risk myelodysplastic syndrome (MDS). While long-term benefits of azacitidine…